Jean Jacques Bienaime - 10 Mar 2023 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
Chief Executive Officer, Director
Signature
/s/ Eric Fleekop, Attorney-in-Fact
Issuer symbol
BMRN
Transactions as of
10 Mar 2023
Net transactions value
-$548,170
Form type
4
Filing time
14 Mar 2023, 19:40:22 UTC
Previous filing
02 Mar 2023
Next filing
17 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Options Exercise $1,017,150 +15,000 +3.1% $67.81 502,856 10 Mar 2023 Direct F1
transaction BMRN Common Stock Sale $1,384,200 -15,000 -3% $92.28 487,856 10 Mar 2023 Direct F1
transaction BMRN Common Stock Options Exercise $542,480 +8,000 +1.6% $67.81 495,856 13 Mar 2023 Direct F2
transaction BMRN Common Stock Sale $723,600 -8,000 -1.6% $90.45 487,856 13 Mar 2023 Direct F2
holding BMRN Common Stock 247,333 10 Mar 2023 Shares held by Jean-Jacques Bienaime Family Trust
holding BMRN Common Stock 100 10 Mar 2023 Shares held as UTMA custodian for child
holding BMRN Common Stock 100 10 Mar 2023 Shares held as UTMA custodian for child

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMRN Stock Option (Right to buy Common Stock) Options Exercise $0 -15,000 -8.7% $0.000000 157,130 10 Mar 2023 Common Stock 15,000 $67.81 Direct F1, F3
transaction BMRN Stock Option (Right to buy Common Stock) Options Exercise $0 -8,000 -5.1% $0.000000 149,130 13 Mar 2023 Common Stock 8,000 $67.81 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Trade made pursuant to a 10b5-1 plan executed on May 3, 2022.
F2 Trade made pursuant to a 10b5-1 plan executed on November 17, 2022.
F3 Reflects the number of options outstanding after the transactions from this specific stock option grant.